Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.14
NXTM's Cash to Debt is ranked higher than
62% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. NXTM: 4.14 )
Ranked among companies with meaningful Cash to Debt only.
NXTM' s Cash to Debt Range Over the Past 10 Years
Min: 0.5  Med: 3.94 Max: No Debt
Current: 4.14
Equity to Asset 0.63
NXTM's Equity to Asset is ranked higher than
59% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NXTM: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
NXTM' s Equity to Asset Range Over the Past 10 Years
Min: -4.58  Med: 0.62 Max: 0.89
Current: 0.63
-4.58
0.89
F-Score: 7
Z-Score: 8.81
M-Score: -2.79
WACC vs ROIC
3.68%
-3.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -1.22
NXTM's Operating margin (%) is ranked lower than
61% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.66 vs. NXTM: -1.22 )
Ranked among companies with meaningful Operating margin (%) only.
NXTM' s Operating margin (%) Range Over the Past 10 Years
Min: -201.29  Med: -11.07 Max: -1.22
Current: -1.22
-201.29
-1.22
Net-margin (%) -1.61
NXTM's Net-margin (%) is ranked lower than
62% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.06 vs. NXTM: -1.61 )
Ranked among companies with meaningful Net-margin (%) only.
NXTM' s Net-margin (%) Range Over the Past 10 Years
Min: -190.42  Med: -13.77 Max: -1.61
Current: -1.61
-190.42
-1.61
ROE (%) -3.01
NXTM's ROE (%) is ranked lower than
64% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. NXTM: -3.01 )
Ranked among companies with meaningful ROE (%) only.
NXTM' s ROE (%) Range Over the Past 10 Years
Min: -54.8  Med: -20.18 Max: -3.01
Current: -3.01
-54.8
-3.01
ROA (%) -1.88
NXTM's ROA (%) is ranked lower than
61% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. NXTM: -1.88 )
Ranked among companies with meaningful ROA (%) only.
NXTM' s ROA (%) Range Over the Past 10 Years
Min: -44.45  Med: -10.45 Max: -1.88
Current: -1.88
-44.45
-1.88
ROC (Joel Greenblatt) (%) -3.19
NXTM's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.16 vs. NXTM: -3.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NXTM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -199.98  Med: -49.81 Max: -3.19
Current: -3.19
-199.98
-3.19
Revenue Growth (3Y)(%) 8.20
NXTM's Revenue Growth (3Y)(%) is ranked higher than
66% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. NXTM: 8.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NXTM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 17.2 Max: 332.9
Current: 8.2
0
332.9
EBITDA Growth (3Y)(%) 7.30
NXTM's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. NXTM: 7.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NXTM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.9  Med: -29.1 Max: 7.3
Current: 7.3
-61.9
7.3
EPS Growth (3Y)(%) -2.60
NXTM's EPS Growth (3Y)(%) is ranked lower than
68% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. NXTM: -2.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NXTM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.6  Med: -24.6 Max: 1.1
Current: -2.6
-34.6
1.1
GuruFocus has detected 3 Warning Signs with NxStage Medical Inc $NXTM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NXTM's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

NXTM Guru Trades in Q4 2015

Jim Simons 361,990 sh (+22.50%)
RS Investment Management 3,775,059 sh (-7.65%)
Steven Cohen 598,300 sh (-39.78%)
» More
Q1 2016

NXTM Guru Trades in Q1 2016

Jim Simons 478,783 sh (+32.26%)
RS Investment Management 3,178,407 sh (-15.81%)
Steven Cohen 325,000 sh (-45.68%)
» More
Q2 2016

NXTM Guru Trades in Q2 2016

Joel Greenblatt 18,781 sh (New)
Paul Tudor Jones 14,241 sh (New)
Steven Cohen Sold Out
RS Investment Management 2,154,390 sh (-32.22%)
Jim Simons 158,483 sh (-66.90%)
» More
Q3 2016

NXTM Guru Trades in Q3 2016

Alan Fournier 397,365 sh (New)
Jim Simons 250,983 sh (+58.37%)
Steven Cohen 200,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NXTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334510    SIC: 3845
Compare:NYSE:HYH, OTCPK:TOPCF, NYSE:HAE, NAS:ICUI, NYSE:GKOS, NAS:MMSI, NAS:PODD, NAS:LMNX, OTCPK:ANSLY, NAS:ATRI, NAS:IRTC, NAS:ANGO, OTCPK:NNCSF, NAS:NVCR, NAS:ELGX, NAS:ATRC, NAS:OSUR, NAS:LMAT, NAS:MLAB, NAS:STAA » details
Traded in other countries:N5X.Germany,
NxStage Medical Inc is a medical device company. The Company develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

NxStage Medical Inc was incorporated on October 20, 1998 under the name Qb Medical, Inc. The Company is a medical technology company that develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. Its product, the System One, was designed to satisfy an unmet clinical need for a system that can deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis centers. The System One is particularly well-suited for home hemodialysis and a range of dialysis therapies that are more practical to deliver in the home setting, including more frequent hemodialysis and nocturnal hemodialysis, which clinical literature suggests provides patients clinical outcomes and improved quality of life. The Company also operates several recently opened NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly. These centers are focused on supporting home therapy with NxStage technology as part of its market development activities to increase home therapy access. The Company operates in three segments including System One, In-Center and Services. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets. Some of its customers in the home market provide outsourced renal dialysis services to some of its customers in the critical care market. Sales of products to both markets are made through dedicated sales forces to dialysis centers and hospitals and delivered directly to the customer, or their patients, with certain products sold through distributors. In addition to specialized sales representatives, the Company also employs nurses in its sales force as clinical educators to support its sales efforts. It has a staff of customer support specialists to assist patients, clinics and hospitals with product orders and deliveries. It also provides technical support 24 hours a day, seven days a week through a dedicated staff of technical support representatives, to respond to questions raised by patients, clinics and hospitals concerning the System One. In-Center segment includes revenues from the sale of blood tubing sets and needles for hemodialysis, for the treatment of ESRD patients at dialysis clinics, and needles for apheresis. In this market, the Company's customers are independent dialysis clinics as well as dialysis clinics that are part of national or regional chains. All of its sales in this market are made through national distributors in order to leverage national networks, shipping efficiencies and existing customer relationships. The Servic

Ratios

vs
industry
vs
history
P/B 8.92
NXTM's P/B is ranked lower than
88% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. NXTM: 8.92 )
Ranked among companies with meaningful P/B only.
NXTM' s P/B Range Over the Past 10 Years
Min: 0.8  Med: 4.57 Max: 14.23
Current: 8.92
0.8
14.23
P/S 4.88
NXTM's P/S is ranked lower than
71% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. NXTM: 4.88 )
Ranked among companies with meaningful P/S only.
NXTM' s P/S Range Over the Past 10 Years
Min: 0.64  Med: 3.57 Max: 15.72
Current: 4.88
0.64
15.72
PFCF 626.13
NXTM's PFCF is ranked lower than
99% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.12 vs. NXTM: 626.13 )
Ranked among companies with meaningful PFCF only.
NXTM' s PFCF Range Over the Past 10 Years
Min: 365.96  Med: 597.73 Max: 8213.33
Current: 626.13
365.96
8213.33
POCF 126.38
NXTM's POCF is ranked lower than
96% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.81 vs. NXTM: 126.38 )
Ranked among companies with meaningful POCF only.
NXTM' s POCF Range Over the Past 10 Years
Min: 71.66  Med: 233.2 Max: 9670
Current: 126.38
71.66
9670
EV-to-EBITDA 60.88
NXTM's EV-to-EBITDA is ranked lower than
91% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.68 vs. NXTM: 60.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
NXTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1804.3  Med: 44.35 Max: 478.5
Current: 60.88
-1804.3
478.5
Current Ratio 2.97
NXTM's Current Ratio is ranked higher than
64% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.44 vs. NXTM: 2.97 )
Ranked among companies with meaningful Current Ratio only.
NXTM' s Current Ratio Range Over the Past 10 Years
Min: 1.71  Med: 3.04 Max: 10.48
Current: 2.97
1.71
10.48
Quick Ratio 2.00
NXTM's Quick Ratio is ranked higher than
63% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. NXTM: 2.00 )
Ranked among companies with meaningful Quick Ratio only.
NXTM' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 2.14 Max: 9.59
Current: 2
0.75
9.59
Days Inventory 71.26
NXTM's Days Inventory is ranked higher than
84% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.20 vs. NXTM: 71.26 )
Ranked among companies with meaningful Days Inventory only.
NXTM' s Days Inventory Range Over the Past 10 Years
Min: 71.26  Med: 91.78 Max: 114.41
Current: 71.26
71.26
114.41
Days Sales Outstanding 30.74
NXTM's Days Sales Outstanding is ranked higher than
93% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.71 vs. NXTM: 30.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
NXTM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.56  Med: 28.95 Max: 75.45
Current: 30.74
26.56
75.45
Days Payable 25.25
NXTM's Days Payable is ranked lower than
89% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.06 vs. NXTM: 25.25 )
Ranked among companies with meaningful Days Payable only.
NXTM' s Days Payable Range Over the Past 10 Years
Min: 19.2  Med: 45.77 Max: 121.1
Current: 25.25
19.2
121.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.60
NXTM's 3-Year Average Share Buyback Ratio is ranked higher than
51% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. NXTM: -2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NXTM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143.2  Med: -10.85 Max: -2.6
Current: -2.6
-143.2
-2.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 70.64
NXTM's Price/Net Current Asset Value is ranked lower than
95% of the 110 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.38 vs. NXTM: 70.64 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NXTM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.77  Med: 39.87 Max: 112.06
Current: 70.64
2.77
112.06
Price/Tangible Book 12.14
NXTM's Price/Tangible Book is ranked lower than
84% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. NXTM: 12.14 )
Ranked among companies with meaningful Price/Tangible Book only.
NXTM' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.38  Med: 6.86 Max: 107.91
Current: 12.14
2.38
107.91
Price/Median PS Value 1.37
NXTM's Price/Median PS Value is ranked lower than
69% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.09 vs. NXTM: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
NXTM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.01 Max: 3.79
Current: 1.37
0.24
3.79
Earnings Yield (Greenblatt) (%) -0.20
NXTM's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. NXTM: -0.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NXTM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -89.8  Med: 0 Max: 0
Current: -0.2
-89.8
0
Forward Rate of Return (Yacktman) (%) 13.26
NXTM's Forward Rate of Return (Yacktman) (%) is ranked higher than
66% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.15 vs. NXTM: 13.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NXTM' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -70.3  Med: -3.6 Max: 14.9
Current: 13.26
-70.3
14.9

More Statistics

Revenue (TTM) (Mil) $363.2
EPS (TTM) $ -0.09
Beta0.17
Short Percentage of Float5.37%
52-Week Range $13.49 - 28.36
Shares Outstanding (Mil)64.76
» More Articles for NXTM

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: MFLX, NXTM, CVRR, CMLP Nov 10 2013 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Mar 18 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Feb 18 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares Jan 21 2011 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 15,000 Shares Jan 20 2011 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 17 2010 
NxStage Medical Inc. (NXTM) Sr. Vice President, CFO Robert S. Brown sells 12,000 Shares Dec 16 2010 
NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,710 Shares Dec 16 2010 

More From Other Websites
NxStage® to Report Fourth Quarter and Full Year 2016 Financial Results Jan 16 2017
Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay Jan 04 2017
Illumina Fettered With Losses: Can It Bounce Back in 2017? Jan 03 2017
Masimo to Launch Advanced Monitoring Technologies in India Jan 03 2017
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3 Jan 02 2017
Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold? Jan 02 2017
Is Baxter Poised to Counter Low Cyclophosphamide Sales? Dec 30 2016
CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions Dec 30 2016
Alere (ALR) Appeals to Reinstate Medicare Billing Privilege Dec 30 2016
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite Dec 30 2016
LabCorp: Covance Drug Prospects Bright, Competition Rife Dec 29 2016
ResMed: SDB Business Faces Risks, Reimbursement a Drag Dec 29 2016
Nutrisystem Declares Multi-Brand Marketing Approach for '17 Dec 29 2016
Myriad Genetics' Unit Releases Favorable Data on Vectra DA Dec 28 2016
Cardiovascular Systems (CSII): Q1 Solid, Net Losses Linger Dec 28 2016
5 Efficient Stocks to Strengthen Your Portfolio Dec 27 2016
Boston Scientific Down on Risks; Innovations Raise Hope Dec 27 2016
Qiagen Poised on Fundamentals, Expansion Plans on Track Dec 23 2016
Myriad Genetics: United Rheumatology Selects Vectra DA Test Dec 23 2016
Henry Schein Named 2016's Best Animal Healthcare Provider Dec 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)